Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Acinetobacter species have emerged as agents of serious nosocomial infections in critically
ill patients. Only a few effective antibiotics are currently available for the treatment of
this pathogen and, therefore, sulbactam is being considered as an alternative treatment
option. The aims of this study were to i) reveal the population pharmacokinetics and ii)
assess the probability of target attainment (PTA) of sulbactam in septic critically ill
patients caused by Acinetobacter spp. infections.
The study was conducted in septic critically ill patients caused by Acinetobacter spp. Each
patient received 2 g every 12 h of sulbactam for 10 days, after which PK studies were carried
out on day 4 of sulbactam therapy and a Monte Carlo simulation was performed to determine the
probability of attaining a specific pharmacodynamic target.